Skip to main content
Erschienen in: Journal of Genetic Counseling 4/2017

30.12.2016 | Original Research

Self-Reported Questionnaire Detects Family History of Cancer in a Pancreatic Cancer Screening Program

verfasst von: Aimee L. Lucas, Adam Tarlecki, Kellie Van Beck, Casey Lipton, Arindam RoyChoudhury, Elana Levinson, Sheila Kumar, Wendy K. Chung, Harold Frucht, Jeanine M. Genkinger

Erschienen in: Journal of Genetic Counseling | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death; approximately 5–10% of PDAC is hereditary. Self-administered health history questionnaires (HHQs) may provide a low-cost method to detail family history (FH) of malignancy. Pancreas Center patients were asked to enroll in a registry; 149 with PDAC completed a HHQ which included FH data. Patients with FH of PDAC, or concern for inherited PDAC syndrome, were separately evaluated in a Prevention Program and additionally met with a genetic counselor (GC) to assess PDAC risk (n = 61). FH obtained through GC and HHQ were compared using Wilcoxon signed-rank sum and generalized linear mixed models with Poisson distribution. Agreement between GC and HHQ risk-assessment was assessed using kappa (κ) statistic. In the Prevention Program, HHQ was as precise in detecting FH of cancer as the GC (all p > 0.05). GC and HHQ demonstrated substantial agreement in risk-stratification of the Prevention Program cohort (κ = 0.73, 95% CI 0.59–0.87.) The sensitivity of the HHQ to detect a patient at elevated risk (i.e., moderate- or high-risk) of PDAC, compared to GC, was 82.9% (95% CI 67.3–92.3%) with a specificity of 95% (95% CI 73.1–99.7%). However, seven patients who were classified as average-risk by the HHQ were found to be at an elevated-risk of PDAC by the GC. In the PDAC cohort, 30/149 (20.1%) reported at least one first-degree relative (FDR) with PDAC. The limited sensitivity of the HHQ to detect patients at elevated risk of PDAC in the Prevention Program cohort suggests that a GC adds value in risk-assessment in this population. The HHQ may offer an opportunity to identify high-risk patients in a PDAC population.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat American Cancer Society. (2016). Cancer Facts & Figures 2016. Atlanta: American Cancer Society. American Cancer Society. (2016). Cancer Facts & Figures 2016. Atlanta: American Cancer Society.
Zurück zum Zitat Applebaum-Shapiro, S. E., Finch, R., Pfutzer, R. H., Hepp, L. A., Gates, L., Amann, S., & Whitcomb, D. C. (2001). Hereditary pancreatitis in North America: the Pittsburgh-Midwest Multi-Center Pancreatic Study Group Study. Pancreatology, 1(5), 439–443.CrossRefPubMed Applebaum-Shapiro, S. E., Finch, R., Pfutzer, R. H., Hepp, L. A., Gates, L., Amann, S., & Whitcomb, D. C. (2001). Hereditary pancreatitis in North America: the Pittsburgh-Midwest Multi-Center Pancreatic Study Group Study. Pancreatology, 1(5), 439–443.CrossRefPubMed
Zurück zum Zitat Arslan, A. A., Helzlsouer, K. J., Kooperberg, C., Shu, X. O., Steplowski, E., Bueno-de-Mesquita, H. B., & Pancreatic Cancer Cohort, C. (2010). Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Archives of Internal Medicine, 170(9), 791–802. doi:10.1001/archinternmed.2010.63.CrossRefPubMedPubMedCentral Arslan, A. A., Helzlsouer, K. J., Kooperberg, C., Shu, X. O., Steplowski, E., Bueno-de-Mesquita, H. B., & Pancreatic Cancer Cohort, C. (2010). Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Archives of Internal Medicine, 170(9), 791–802. doi:10.​1001/​archinternmed.​2010.​63.CrossRefPubMedPubMedCentral
Zurück zum Zitat Brentnall, T. A., Bronner, M. P., Byrd, D. R., Haggitt, R. C., & Kimmey, M. B. (1999). Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Annals of Internal Medicine, 131(4), 247–255.CrossRefPubMed Brentnall, T. A., Bronner, M. P., Byrd, D. R., Haggitt, R. C., & Kimmey, M. B. (1999). Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Annals of Internal Medicine, 131(4), 247–255.CrossRefPubMed
Zurück zum Zitat Brown, H., & Prescott, R. (2015). Applied mixed models in medicine (Third edition. ed.). Chichester, West Sussex; Hoboken: John Wiley & Sons Inc. Brown, H., & Prescott, R. (2015). Applied mixed models in medicine (Third edition. ed.). Chichester, West Sussex; Hoboken: John Wiley & Sons Inc.
Zurück zum Zitat Buchanan, A. H., Datta, S. K., Skinner, C. S., Hollowell, G. P., Beresford, H. F., Freeland, T., & Adams, M. B. (2015). Randomized trial of telegenetics vs. in-person cancer genetic counseling: cost, patient satisfaction and attendance. Journal of Genetic Counseling, 24(6), 961–970. doi:10.1007/s10897-015-9836-6.CrossRefPubMedPubMedCentral Buchanan, A. H., Datta, S. K., Skinner, C. S., Hollowell, G. P., Beresford, H. F., Freeland, T., & Adams, M. B. (2015). Randomized trial of telegenetics vs. in-person cancer genetic counseling: cost, patient satisfaction and attendance. Journal of Genetic Counseling, 24(6), 961–970. doi:10.​1007/​s10897-015-9836-6.CrossRefPubMedPubMedCentral
Zurück zum Zitat Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J. W., Kamel, I., & Bruno, M. (2012a). International cancer of the pancreas screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. doi:10.1136/gutjnl-2012-303108. Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J. W., Kamel, I., & Bruno, M. (2012a). International cancer of the pancreas screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. doi:10.​1136/​gutjnl-2012-303108.
Zurück zum Zitat Couch, F. J., Johnson, M. R., Rabe, K. G., Brune, K., de Andrade, M., Goggins, M., & Hruban, R. H. (2007). The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiology, Biomarkers and Prevention, 16(2), 342–346. doi:10.1158/1055-9965.EPI-06-0783.CrossRefPubMed Couch, F. J., Johnson, M. R., Rabe, K. G., Brune, K., de Andrade, M., Goggins, M., & Hruban, R. H. (2007). The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiology, Biomarkers and Prevention, 16(2), 342–346. doi:10.​1158/​1055-9965.​EPI-06-0783.CrossRefPubMed
Zurück zum Zitat Egawa, S., Takeda, K., Fukuyama, S., Motoi, F., Sunamura, M., & Matsuno, S. (2004). Clinicopathological aspects of small pancreatic cancer. Pancreas, 28(3), 235–240.CrossRefPubMed Egawa, S., Takeda, K., Fukuyama, S., Motoi, F., Sunamura, M., & Matsuno, S. (2004). Clinicopathological aspects of small pancreatic cancer. Pancreas, 28(3), 235–240.CrossRefPubMed
Zurück zum Zitat Genkinger, J. M., Spiegelman, D., Anderson, K. E., Bergkvist, L., Bernstein, L., van den Brandt, P. A., & Smith-Warner, S. A. (2009). Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiology, Biomarkers and Prevention, 18(3), 765–776. doi:10.1158/1055-9965.EPI-08-0880.CrossRefPubMedPubMedCentral Genkinger, J. M., Spiegelman, D., Anderson, K. E., Bergkvist, L., Bernstein, L., van den Brandt, P. A., & Smith-Warner, S. A. (2009). Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiology, Biomarkers and Prevention, 18(3), 765–776. doi:10.​1158/​1055-9965.​EPI-08-0880.CrossRefPubMedPubMedCentral
Zurück zum Zitat Giardiello, F., Brensinger, J., Tersmette, A., Goodman, S., Petersen, G., Booker, S., & Offerhaus, J. (2000). Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology, 119(6), 1447–1453.CrossRefPubMed Giardiello, F., Brensinger, J., Tersmette, A., Goodman, S., Petersen, G., Booker, S., & Offerhaus, J. (2000). Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology, 119(6), 1447–1453.CrossRefPubMed
Zurück zum Zitat Hahn, S. A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Gerdes, B., & Bartsch, D. (2003). BRCA2 germline mutations in familial pancreatic carcinoma. Gastroenterology, 124(4), A548–A548.CrossRef Hahn, S. A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Gerdes, B., & Bartsch, D. (2003). BRCA2 germline mutations in familial pancreatic carcinoma. Gastroenterology, 124(4), A548–A548.CrossRef
Zurück zum Zitat Howes, N., Lerch, M. M., Greenhalf, W., Stocken, D. D., Ellis, I., Simon, P., & Pancreatic, C. (2004). Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clinical Gastroenterology and Hepatology, 2(3), 252–261.CrossRefPubMed Howes, N., Lerch, M. M., Greenhalf, W., Stocken, D. D., Ellis, I., Simon, P., & Pancreatic, C. (2004). Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clinical Gastroenterology and Hepatology, 2(3), 252–261.CrossRefPubMed
Zurück zum Zitat Ishikawa, O., Ohigashi, H., Imaoka, S., Nakaizumi, A., Uehara, H., Kitamura, T., & Kuroda, C. (1999). Minute carcinoma of the pancreas measuring 1 cm or less in diameter--collective review of Japanese case reports. Hepato-Gastroenterology, 46(25), 8–15.PubMed Ishikawa, O., Ohigashi, H., Imaoka, S., Nakaizumi, A., Uehara, H., Kitamura, T., & Kuroda, C. (1999). Minute carcinoma of the pancreas measuring 1 cm or less in diameter--collective review of Japanese case reports. Hepato-Gastroenterology, 46(25), 8–15.PubMed
Zurück zum Zitat Klein, A. P., Hruban, R. H., Brune, K. A., Petersen, G. M., & Goggins, M. (2001). Familial pancreatic cancer. Cancer Journal, 7(4), 266–273. Klein, A. P., Hruban, R. H., Brune, K. A., Petersen, G. M., & Goggins, M. (2001). Familial pancreatic cancer. Cancer Journal, 7(4), 266–273.
Zurück zum Zitat Klein, A. P., Brune, K. A., Petersen, G. M., Goggins, M., Tersmette, A. C., Offerhaus, G. J., & Hruban, R. H. (2004). Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Research, 64(7), 2634–2638.CrossRefPubMed Klein, A. P., Brune, K. A., Petersen, G. M., Goggins, M., Tersmette, A. C., Offerhaus, G. J., & Hruban, R. H. (2004). Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Research, 64(7), 2634–2638.CrossRefPubMed
Zurück zum Zitat Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33(1), 159–174.CrossRefPubMed Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33(1), 159–174.CrossRefPubMed
Zurück zum Zitat Lucas, A. L., Shakya, R., Lipsyc, M. D., Mitchel, E. B., Kumar, S., Hwang, C., & Frucht, H. (2013). High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clinical Cancer Research, 19(13), 3396–3403. doi:10.1158/1078-0432.CCR-12-3020.CrossRefPubMedPubMedCentral Lucas, A. L., Shakya, R., Lipsyc, M. D., Mitchel, E. B., Kumar, S., Hwang, C., & Frucht, H. (2013). High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clinical Cancer Research, 19(13), 3396–3403. doi:10.​1158/​1078-0432.​CCR-12-3020.CrossRefPubMedPubMedCentral
Zurück zum Zitat Lucas, A. L., Frado, L. E., Hwang, C., Kumar, S., Khanna, L. G., Levinson, E. J., & Frucht, H. (2014). BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer, 120(13), 1960–1967. doi:10.1002/cncr.28662.CrossRefPubMedPubMedCentral Lucas, A. L., Frado, L. E., Hwang, C., Kumar, S., Khanna, L. G., Levinson, E. J., & Frucht, H. (2014). BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer, 120(13), 1960–1967. doi:10.​1002/​cncr.​28662.CrossRefPubMedPubMedCentral
Zurück zum Zitat Lucenteforte, E., La Vecchia, C., Silverman, D., Petersen, G. M., Bracci, P. M., Ji, B. T., & Duell, E. J. (2012). Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case–control Consortium (PanC4). Annals of Oncology, 23(2), 374–382. doi:10.1093/annonc/mdr120.CrossRefPubMed Lucenteforte, E., La Vecchia, C., Silverman, D., Petersen, G. M., Bracci, P. M., Ji, B. T., & Duell, E. J. (2012). Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case–control Consortium (PanC4). Annals of Oncology, 23(2), 374–382. doi:10.​1093/​annonc/​mdr120.CrossRefPubMed
Zurück zum Zitat Michaud, D. S., Vrieling, A., Jiao, L., Mendelsohn, J. B., Steplowski, E., Lynch, S. M., & Stolzenberg-Solomon, R. Z. (2010). Alcohol intake and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan). Cancer Causes and Control, 21(8), 1213–1225. doi:10.1007/s10552-010-9548-z.CrossRefPubMedPubMedCentral Michaud, D. S., Vrieling, A., Jiao, L., Mendelsohn, J. B., Steplowski, E., Lynch, S. M., & Stolzenberg-Solomon, R. Z. (2010). Alcohol intake and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan). Cancer Causes and Control, 21(8), 1213–1225. doi:10.​1007/​s10552-010-9548-z.CrossRefPubMedPubMedCentral
Zurück zum Zitat Murphy, K. M., Brune, K. A., Griffin, C., Sollenberger, J. E., Petersen, G. M., Bansal, R., & Kern, S. E. (2002). Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Research, 62(13), 3789–3793.PubMed Murphy, K. M., Brune, K. A., Griffin, C., Sollenberger, J. E., Petersen, G. M., Bansal, R., & Kern, S. E. (2002). Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Research, 62(13), 3789–3793.PubMed
Zurück zum Zitat Pandharipande, P. V., Heberle, C., Dowling, E. C., Kong, C. Y., Tramontano, A., Perzan, K. E., & Hur, C. (2015). Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Radiology, 275(1), 177–187. doi:10.1148/radiol.14141282.CrossRefPubMed Pandharipande, P. V., Heberle, C., Dowling, E. C., Kong, C. Y., Tramontano, A., Perzan, K. E., & Hur, C. (2015). Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Radiology, 275(1), 177–187. doi:10.​1148/​radiol.​14141282.CrossRefPubMed
Zurück zum Zitat SAS Institute Inc. (2011). SAS® 9.3 System Options: Reference (2nd ed.). Cary, NC: SAS Institute Inc. SAS Institute Inc. (2011). SAS® 9.3 System Options: Reference (2nd ed.). Cary, NC: SAS Institute Inc.
Zurück zum Zitat Shi, C., Hruban, R. H., & Klein, A. P. (2009). Familial pancreatic cancer. Archives of Pathology and Laboratory Medicine, 133(3), 365–374.PubMed Shi, C., Hruban, R. H., & Klein, A. P. (2009). Familial pancreatic cancer. Archives of Pathology and Laboratory Medicine, 133(3), 365–374.PubMed
Zurück zum Zitat Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 64(1), 9–29. doi:10.3322/caac.21208. Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 64(1), 9–29. doi:10.​3322/​caac.​21208.
Zurück zum Zitat Spanknebel, K., & Conlon, K. C. (2001). Advances in the surgical management of pancreatic cancer. Cancer Journal, 7(4), 312–323. Spanknebel, K., & Conlon, K. C. (2001). Advances in the surgical management of pancreatic cancer. Cancer Journal, 7(4), 312–323.
Zurück zum Zitat Thompson, D., & Easton, D. F. (2002). Cancer Incidence in BRCA1 mutation carriers. Journal of the National Cancer Institute, 94(18), 1358–1365.CrossRefPubMed Thompson, D., & Easton, D. F. (2002). Cancer Incidence in BRCA1 mutation carriers. Journal of the National Cancer Institute, 94(18), 1358–1365.CrossRefPubMed
Zurück zum Zitat U.S. Department of Health and Human Services. (2014). The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, G. U. S. D. U.S. Department of Health and Human Services. (2014). The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, G. U. S. D.
Zurück zum Zitat Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Ruschoff, J., & Srivastava, S. (2004). Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261–268.CrossRefPubMedPubMedCentral Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Ruschoff, J., & Srivastava, S. (2004). Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261–268.CrossRefPubMedPubMedCentral
Zurück zum Zitat Vasen, H., Ibrahim, I., Ponce, C. G., Slater, E. P., Matthai, E., Carrato, A., & Bartsch, D. K. (2016). Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. Journal of Clinical Oncology, 34(17), 2010–2019. doi:10.1200/JCO.2015.64.0730.CrossRefPubMed Vasen, H., Ibrahim, I., Ponce, C. G., Slater, E. P., Matthai, E., Carrato, A., & Bartsch, D. K. (2016). Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. Journal of Clinical Oncology, 34(17), 2010–2019. doi:10.​1200/​JCO.​2015.​64.​0730.CrossRefPubMed
Zurück zum Zitat Verna, E. C., Hwang, C., Stevens, P. D., Rotterdam, H., Stavropoulos, S. N., Sy, C. D., & Frucht, H. (2010). Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clinical Cancer Research, 16(20), 5028–5037. doi:10.1158/1078-0432.CCR-09-3209.CrossRefPubMed Verna, E. C., Hwang, C., Stevens, P. D., Rotterdam, H., Stavropoulos, S. N., Sy, C. D., & Frucht, H. (2010). Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clinical Cancer Research, 16(20), 5028–5037. doi:10.​1158/​1078-0432.​CCR-09-3209.CrossRefPubMed
Zurück zum Zitat Vinarsky, V., Fine, R. L., Assaad, A., Qian, Y., Chabot, J. A., Su, G. H., & Frucht, H. (2009). Head and neck squamous cell carcinoma in FAMMM syndrome. Head & Neck, 31(11), 1524–1527. doi:10.1002/hed.21050.CrossRef Vinarsky, V., Fine, R. L., Assaad, A., Qian, Y., Chabot, J. A., Su, G. H., & Frucht, H. (2009). Head and neck squamous cell carcinoma in FAMMM syndrome. Head & Neck, 31(11), 1524–1527. doi:10.​1002/​hed.​21050.CrossRef
Metadaten
Titel
Self-Reported Questionnaire Detects Family History of Cancer in a Pancreatic Cancer Screening Program
verfasst von
Aimee L. Lucas
Adam Tarlecki
Kellie Van Beck
Casey Lipton
Arindam RoyChoudhury
Elana Levinson
Sheila Kumar
Wendy K. Chung
Harold Frucht
Jeanine M. Genkinger
Publikationsdatum
30.12.2016
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling / Ausgabe 4/2017
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-016-0057-4

Weitere Artikel der Ausgabe 4/2017

Journal of Genetic Counseling 4/2017 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.